NPH is an intermediate-acting insulin whose peak effect commonly occurs about 4 to 12 hours after subcutaneous administration. For a 0700 dose, the expected peak-risk window is approximately 1100 to 1900, making option 3 correct. The earlier ranges are more consistent with the onset or peak of shorter-acting insulin, while 2300 to 0100 is later than the usual NPH peak window. Individual response varies, so glucose trends and hypoglycemia symptoms must also be monitored.
In-depth explanation
Clinical reasoning summary
NPH insulin has a variable intermediate-action profile and commonly peaks several hours after injection. After a 0700 dose, monitor most closely from about 1100 to 1900, ensure meals and snacks are available, and watch for hypoglycemia.
For study reference only. Always follow current clinical guidelines and your institution’s protocols.